Cellectis sets June 25, 2026 shareholder meeting

Cellectis S.A. has scheduled its annual shareholders general meeting for June 25, 2026 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.

Rhea-AI Filing Summary

Cellectis S.A. has scheduled its annual shareholders general meeting for June 25, 2026 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France. The formal notice and related meeting information are available on the company’s investor website.

Key Figures

Meeting date: June 25, 2026 Meeting time: 2:30 p.m. CET Meeting venue: Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris +1 more

4 metrics

Meeting date June 25, 2026 Annual shareholders general meeting

Meeting time 2:30 p.m. CET Annual shareholders general meeting

Meeting venue Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris Location of 2026 annual shareholders meeting

Headquarters location Paris, France Corporate headquarters of Cellectis

Key Terms

Form 6-K, foreign private issuer, annual general meeting, gene-editing platform, +2 more

6 terms

Form 6-K regulatory

"Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"

A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.

foreign private issuer regulatory

"REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

annual general meeting financial

"Cellectis’ Annual Shareholders General Meeting to be Held on June 25, 2026"

gene-editing platform technical

"using its pioneering gene-editing platform to develop life-saving cell and gene therapies"

CAR T immunotherapies technical

"an allogeneic approach for CAR T immunotherapies in oncology"

allogeneic approach technical

"The company utilizes an allogeneic approach for CAR T immunotherapies"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Cellectis (CLLS) holding its 2026 annual shareholders meeting?

Cellectis will hold its 2026 annual shareholders general meeting on June 25, 2026 at 2:30 p.m. CET. The meeting will take place in Paris and is described in more detail in the notice available on the company’s investor website.

Where will the Cellectis (CLLS) 2026 annual general meeting take place?

The 2026 annual general meeting will be held at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France. This physical location is specified in the company’s announcement for shareholders planning to attend in person.

Where can investors find the Cellectis 2026 shareholders meeting notice?

The notice of Cellectis’ 2026 annual general meeting is available on its website under the general meetings section. Investors can access it via the company’s investor relations page at https://www.cellectis.com/en/investors/general-meetings/ for full details.

What type of company is Cellectis (CLLS)?

Cellectis is a clinical-stage biotechnology company focused on gene editing to develop cell and gene therapies. It uses an allogeneic, or off-the-shelf, approach for CAR T immunotherapies in oncology and gene therapies for other indications, supported by in-house manufacturing capabilities.

On which markets are Cellectis shares listed?

Cellectis shares are listed on the Nasdaq Global Market under the ticker CLLS and on Euronext Growth under the ticker ALCLS. These dual listings provide access to both U.S. and European equity investors interested in the company’s biotechnology activities.

How can investors contact Cellectis investor relations about the meeting?

Investors can contact Cellectis investor relations by emailing investors@cellectis.com, addressed to Arthur Stril, Chief Financial Officer and Chief Business Officer. This contact is provided for questions related to the company, including those concerning the annual general meeting arrangements.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/20/2026 - 04:35 PM Learn about SEC filing dates

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

Date of Report: May 20, 2026

Commission File Number: 001-36891

Cellectis S.A.
(Exact Name of registrant as specified in its charter)

8, rue de la Croix Jarry
75013 Paris, France
+33 1 81 69 16 00
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

EXHIBIT INDEX

Exhibit		Title
99.1		Press Release dated May 20, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Cellectis S.A.
		(Registrant)
Date: May 20, 2026		/s/ André Choulika
		André Choulika
		Chief Executive Officer

EXHIBIT 99.1

Cellectis’ Annual Shareholders General Meeting to be Held on June 25, 2026

NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold its annual general meeting on June 25, 2026 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.

The notice of meeting is available on the Cellectis website: https://www.cellectis.com/en/investors/general-meetings/

About Cellectis     
Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications. With its in-house manufacturing capabilities, Cellectis is one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish.     
    
Cellectis’ headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).
To find out more, visit www.cellectis.com and follow Cellectis on LinkedIn and X.  

For further information on Cellectis, please contact:         
     
Media contacts:              
Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93      

Investor Relations contact:           
Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com

Attachment

• Shareholder's meeting announcement PR_ENGLISH.pdf (https://ml.globenewswire.com/Resource/Download/237f5979-2016-4b99-909a-a37de1d30ac6)

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE 3.4 KB